Approval · Notice of Compliance 13192 · 2012
PMS-MEMANTINE: Notice of Compliance 13192
Issued April 4, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13192
- Date
- April 4, 2012
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- New Strength
- Therapeutic class
- N-Methyl-D-Aspartate (NMDA) Receptor Antagonist
- Canadian reference product
- EBIXA (Lundbeck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PMS-MEMANTINE | 02382830 | Marketed |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 5 MG per TAB